Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q969Q4
UPID:
ARL11_HUMAN
Alternative names:
ADP-ribosylation factor-like tumor suppressor protein 1
Alternative UPACC:
Q969Q4
Background:
ADP-ribosylation factor-like protein 11, alternatively known as ADP-ribosylation factor-like tumor suppressor protein 1, plays a pivotal role in cellular processes, including apoptosis. Its potential as a tumor suppressor highlights its importance in cellular homeostasis and disease prevention.
Therapeutic significance:
The protein's association with chronic lymphocytic leukemia, a condition characterized by the accumulation of functionally incompetent B-lymphocytes, underscores its therapeutic significance. Understanding the role of ADP-ribosylation factor-like protein 11 could open doors to potential therapeutic strategies for managing this heterogeneous disease.